The Potential for Liquid Biopsies in the Precision Medical Treatment of Breast Cancer

Overview

Journal Cancer Biol Med

Specialty Oncology

Date 2016 May 5

PMID 27144060

Citations 11

Authors

Victoria A Forte

Dany K Barrak

Mostafa Elhodaky

Lily Tung

Anson Snow

Julie E Lang

Affiliations

Soon will be listed here.

Abstract

Currently the clinical management of breast cancer relies on relatively few prognostic/predictive clinical markers (estrogen receptor, progesterone receptor, HER2), based on primary tumor biology. Circulating biomarkers, such as circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) may enhance our treatment options by focusing on the very cells that are the direct precursors of distant metastatic disease, and probably inherently different than the primary tumor's biology. To shift the current clinical paradigm, assessing tumor biology in real time by molecularly profiling CTCs or ctDNA may serve to discover therapeutic targets, detect minimal residual disease and predict response to treatment. This review serves to elucidate the detection, characterization, and clinical application of CTCs and ctDNA with the goal of precision treatment of breast cancer.

Citing Articles

Efficient capture of circulating tumor cells with low molecular weight folate receptor-specific ligands.

Hu Y, Chen D, Napoleon J, Srinivasarao M, Singhal S, Savran C Sci Rep. 2022; 12(1):8555.

PMID: 35595733 PMC: 9122947. DOI: 10.1038/s41598-022-12118-3.

Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer.

Gobbini E, Swalduz A, Giaj Levra M, Ortiz-Cuaran S, Toffart A, Perol M Cancers (Basel). 2020; 12(11).

PMID: 33114393 PMC: 7693855. DOI: 10.3390/cancers12113112.

Circulating Tumor Cells: From the Laboratory to the Cancer Clinic.

Agashe R, Kurzrock R Cancers (Basel). 2020; 12(9).

PMID: 32825548 PMC: 7564158. DOI: 10.3390/cancers12092361.

The current status of the clinical utility of liquid biopsies in cancer.

Snow A, Chen D, Lang J Expert Rev Mol Diagn. 2019; 19(11):1031-1041.

PMID: 31482746 PMC: 6981296. DOI: 10.1080/14737159.2019.1664290.

SIRT1 and Estrogen Signaling Cooperation for Breast Cancer Onset and Progression.

Liarte S, Alonso-Romero J, Nicolas F Front Endocrinol (Lausanne). 2018; 9:552.

PMID: 30319540 PMC: 6170604. DOI: 10.3389/fendo.2018.00552.

References

Lucci A, Hall C, Lodhi A, Bhattacharyya A, Anderson A, Xiao L . Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012; 13(7):688-95. DOI: 10.1016/S1470-2045(12)70209-7. View

Liu Z, Fusi A, Schmittel A, Tinhofer I, Schneider A, Keilholz U . Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine. Cancer Biol Ther. 2010; 10(9):860-4. DOI: 10.4161/cbt.10.9.13323. View

Polzer B, Medoro G, Pasch S, Fontana F, Zorzino L, Pestka A . Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med. 2014; 6(11):1371-86. PMC: 4237466. DOI: 10.15252/emmm.201404033. View

Schiavon G, Hrebien S, Garcia-Murillas I, Cutts R, Pearson A, Tarazona N . Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015; 7(313):313ra182. PMC: 4998737. DOI: 10.1126/scitranslmed.aac7551. View

Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann E . Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res. 2013; 73(10):2965-75. DOI: 10.1158/0008-5472.CAN-12-4140. View

Schramm A, Friedl T, Schochter F, Scholz C, de Gregorio N, Huober J . Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program. Arch Gynecol Obstet. 2015; 293(2):271-81. DOI: 10.1007/s00404-015-3879-7. View

Liedtke C, Broglio K, Moulder S, Hsu L, Kau S, Symmans W . Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009; 20(12):1953-8. PMC: 2791352. DOI: 10.1093/annonc/mdp263. View

Rak Tkaczuk K, Goloubeva O, Tait N, Feldman F, Tan M, Lum Z . The significance of circulating epithelial cells in Breast Cancer patients by a novel negative selection method. Breast Cancer Res Treat. 2007; 111(2):355-64. DOI: 10.1007/s10549-007-9771-9. View

Cruz I, Ciudad J, Cruz J, Ramos M, Gomez-Alonso A, Adansa J . Evaluation of multiparameter flow cytometry for the detection of breast cancer tumor cells in blood samples. Am J Clin Pathol. 2005; 123(1):66-74. DOI: 10.1309/wp3qwkvjfydhhxqd. View

10.

Tang W, Zhu J, Su S, Wu W, Liu Q, Su F . MiR-27 as a prognostic marker for breast cancer progression and patient survival. PLoS One. 2012; 7(12):e51702. PMC: 3519894. DOI: 10.1371/journal.pone.0051702. View

11.

Mehes G, Witt A, Kubista E, Ambros P . Circulating breast cancer cells are frequently apoptotic. Am J Pathol. 2001; 159(1):17-20. PMC: 1850424. DOI: 10.1016/S0002-9440(10)61667-7. View

12.

Chudziak J, Burt D, Mohan S, Rothwell D, Mesquita B, Antonello J . Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer. Analyst. 2015; 141(2):669-78. DOI: 10.1039/c5an02156a. View

13.

Zheng S, Lin H, Lu B, Williams A, Datar R, Cote R . 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices. 2010; 13(1):203-13. PMC: 3809998. DOI: 10.1007/s10544-010-9485-3. View

14.

Higuchi R, Fockler C, Dollinger G, Watson R . Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (N Y). 1993; 11(9):1026-30. DOI: 10.1038/nbt0993-1026. View

15.

Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T . Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014; 106(5). PMC: 4112925. DOI: 10.1093/jnci/dju066. View

16.

Lohr J, Adalsteinsson V, Cibulskis K, Choudhury A, Rosenberg M, Cruz-Gordillo P . Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014; 32(5):479-84. PMC: 4034575. DOI: 10.1038/nbt.2892. View

17.

Rossi E, Basso U, Celadin R, Zilio F, Pucciarelli S, Aieta M . M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin Cancer Res. 2010; 16(21):5233-43. DOI: 10.1158/1078-0432.CCR-10-1449. View

18.

Spiliotaki M, Mavroudis D, Kapranou K, Markomanolaki H, Kallergi G, Koinis F . Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. Breast Cancer Res. 2014; 16(6):485. PMC: 4303210. DOI: 10.1186/s13058-014-0485-8. View

19.

Hou H, Warkiani M, Khoo B, Li Z, Soo R, Tan D . Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep. 2013; 3:1259. PMC: 3569917. DOI: 10.1038/srep01259. View

20.

Ntouroupi T, Ashraf S, McGregor S, Turney B, Seppo A, Kim Y . Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br J Cancer. 2008; 99(5):789-95. PMC: 2528135. DOI: 10.1038/sj.bjc.6604545. View